We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-7.6%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.27B
AUM Growth
-$1.19B
Cap. Flow
-$403M
Cap. Flow %
-7.65%
Top 10 Hldgs %
38.7%
Holding
148
New
20
Increased
18
Reduced
35
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$175M
2
HUM icon
Humana
HUM
+$51M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$50.2M
4
BLU
BELLUS Health Inc.
BLU
+$49.6M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$41M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$66.7M
2
BSX icon
Boston Scientific
BSX
+$62.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$61M
4
MRK icon
Merck
MRK
+$51.7M
5
ILMN icon
Illumina
ILMN
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Financials 1.42%
3 Miscellaneous 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$13.9B
$69.2M 1.31%
3,912,900
– –
ABT icon
27
Abbott
ABT
$177B
$68.8M 1.31%
822,400
-115,600
-12% -$9.82M
PTCT icon
28
PTC Therapeutics
PTCT
$5.5B
$66.3M 1.26%
1,958,900
-130,800
-6% -$5.69M
REGN icon
29
Regeneron Pharmaceuticals
REGN
$80.5B
$63.3M 1.2%
228,100
+12,300
+6% +$3.64M
SRPT icon
30
Sarepta Therapeutics
SRPT
$2.21B
$63.1M 1.2%
837,349
+8,949
+1% +$1.06M
ELV icon
31
Elevance Health
ELV
$91.2B
$61.1M 1.16%
254,600
-107,000
-30% -$29.3M
DXCM icon
32
DexCom
DXCM
$32.8B
$57.3M 1.09%
1,536,000
+484,400
+46% +$18.8M
MGTX icon
33
MeiraGTx Holdings
MGTX
$1.21B
$53.4M 1.01%
3,349,060
+762,109
+29% +$17.7M
HUM icon
34
Humana
HUM
$47.5B
$46.5M 0.88%
+181,800
New +$51M
PRNB
35
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$45.3M 0.86%
1,605,713
– –
ARVN icon
36
Arvinas
ARVN
$542M
$45.2M 0.86%
2,095,283
-583,527
-22% -$14.3M
BLU
37
DELISTED
BELLUS Health Inc.
BLU
$45.1M 0.86%
+7,025,832
New +$49.6M
BOLD
38
DELISTED
Audentes Therapeutics, Inc
BOLD
$44.6M 0.85%
1,588,069
-125,000
-7% -$4.27M
CI icon
39
Cigna
CI
$76.6B
$44.3M 0.84%
291,600
+39,000
+15% +$6.35M
ACET icon
40
Adicet Bio
ACET
$76.8M
$42.7M 0.81%
43,128
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.7M 0.79%
+535,143
New +$50.2M
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$40.8M 0.77%
783,032
-172,268
-18% -$9.16M
ATNX
43
DELISTED
Athenex, Inc. Common Stock
ATNX
$40.3M 0.76%
165,446
-26,561
-14% -$8.68M
TNDM icon
44
Tandem Diabetes Care
TNDM
$1.16B
$39.2M 0.74%
664,390
+93,600
+16% +$5.97M
RARE icon
45
Ultragenyx Pharmaceutical
RARE
$1.3B
$35.7M 0.68%
834,313
+754,706
+948% +$41M
ARGX icon
46
argenx
ARGX
$62.4B
$35.4M 0.67%
310,400
– –
HARP
47
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$33.4M 0.63%
244,641
– –
QURE icon
48
uniQure
QURE
$3.03B
$33M 0.63%
839,600
-58,200
-6% -$3.36M
CRNX
49
DELISTED
Crinetics Pharmaceuticals
CRNX
$30.7M 0.58%
2,039,282
– –
ARQL
50
DELISTED
Arqule Inc
ARQL
$26.5M 0.5%
3,701,273
+2,701,273
+270% +$25.4M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2019 Portfolio in Review

As of Q3 2019, OrbiMed held 148 positions worth $5.27B, down 18% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $403M in Q3 2019, closing 32 positions and reducing 35 holdings. Its most notable exit was Agilent Technologies, an estimated $66.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, OrbiMed opened a new position in SpringWorks Therapeutics worth $161M.

  • OrbiMed's largest Q3 2019 buy was SpringWorks Therapeutics: 7,406,307 shares worth $161M.
  • OrbiMed added most to Ultragenyx Pharmaceutical in Q3 2019, an estimated $41M increase.
  • OrbiMed's biggest Q3 2019 reduction was Boston Scientific, cutting an estimated $62.9M.
  • OrbiMed fully exited Agilent Technologies in Q3 2019, selling an estimated $66.7M.
  • OrbiMed's ten largest holdings make up 39% of its $5.27B portfolio in Q3 2019.
  • OrbiMed opened 20 new positions and closed 32 in Q3 2019.
  • OrbiMed's portfolio value fell 18% quarter-over-quarter to $5.27B.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.